Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century

References

• Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40:463–471.
   PubMed Web of Science ®Google Scholar
• Spalding KL. Retrospective birth dating of cells in humans. Cell. 2005;122:133–143.
   PubMed Web of Science ®Google Scholar
• McGuckin MA. Mucin dynamics and enteric pathogens. Nat Rev Microbiol. 2011;9:265–278.
   PubMed Web of Science ®Google Scholar
• Klarhöfer M, Csapo B, Balassy C, et al. High-resolution blood flow velocity measurements in the human finger. Magn Reson Med. 2001;45:716–719.
   PubMed Web of Science ®Google Scholar
• Guo C-L, Harris NC, Wijeratne SS, et al. Multiscale mechanobiology: mechanics at the molecular, cellular, and tissue levels. Cell Biosci. 2013;3:25.
   PubMed Web of Science ®Google Scholar
• Milo R. What is the total number of protein molecules per cell volume? A call to rethink some published values. Bioessays. 2013;35:1050–1055.
   PubMed Web of Science ®Google Scholar
• Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng. 2004;6:41–75.
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Cook WG, et al., editors. Handbook of pharmaceutical excipients. 7th ed. London (UK): Pharmaceutical Press; 2012.
   Google Scholar
• Heller J. Controlled release of biologically active compounds from bioerodible polymers. Biomaterials. 1980;1:51–57.
   PubMed Web of Science ®Google Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–360.
   PubMed Web of Science ®Google Scholar
• Chiellini E, Giusti P, editors. Polymers in medicine: biomedical and pharmacological applications. New York: Plenum Press; 1983.
   Google Scholar
• Duncan R, Kopecek J. Soluble synthetic polymers as potential drug carriers. Adv Polymer Sci. 1984;57:51–101.
   Web of Science ®Google Scholar
• Duncan R. Polymer therapeutics: top 10 selling pharmaceuticals: what next? J Control Release. 2014;190:371–380.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev. 2013;65:60–70.
   PubMed Web of Science ®Google Scholar
• de Duve C, de Barsy T, Poole B, et al. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974;23:2495–2531.
   PubMed Web of Science ®Google Scholar
• de Duve C. The joy of discovery. Nature. 2010;467:S5.
   PubMed Web of Science ®Google Scholar
• Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci C Polym Symp. 1975;51:135–153.
   Google Scholar
• Newell DR, Searle KM, Westwood NB, et al. Professor Tom Connors and the development of novel cancer therapies by the phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer. 2003;89:437–454.
   PubMed Web of Science ®Google Scholar
• Duncan R, Pratten MK. Membrane economics in endocytic systems. J Theor Biol. 1977;66:727–735.
   PubMed Web of Science ®Google Scholar
• Xu H, Ren D. Lysosomal physiology. Annu Rev Physiol. 2015;77:57–80.
   PubMed Web of Science ®Google Scholar
• Maxfield FR. Role of endosomes and lysosomes in human disease. Cold Spring Harb Perspect Biol. 2014;6:a016931.
   PubMed Web of Science ®Google Scholar
• Duncan R, Richardson SCW. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharm. 2012;9:2380–2402.
   PubMed Web of Science ®Google Scholar
• Duncan R, Seymour LCW, Scarlett L, et al. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim Biophys Acta. 1986;880:62–71.
   PubMed Web of Science ®Google Scholar
• Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–132.
   PubMedGoogle Scholar
• Harris RL, van den Berg CW, Bowen DJ. ASGR1 and ASGR2, the genes that encode the asialoglycoprotein receptor (Ashwell Receptor), are expressed in peripheral blood monocytes and show interindividual differences in transcript profile. Mol Biol Int. 2012;2012:283974.
   PubMedGoogle Scholar
• Vasey P, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res. 1999;5:83–94.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20:1668–1676.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Duncan R, Seymour LW, O'Hare KB, et al. Preclinical evaluation of polymer-bound doxorubicin. J Control Rel. 1992;19:331–346.
   Google Scholar
• Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009;61:1131–1148.
   PubMed Web of Science ®Google Scholar
• Gianasi E, Wasil M, Evagorou EG, et al. HPMA copolymer platinates as novel antitumor agents: in-vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer. 1999;35:994–1002.
   PubMed Web of Science ®Google Scholar
• Gianasi E, Buckley RG, Latigo J, et al. HPMA copolymer platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J Drug Target. 2002;10:549–556.
   PubMed Web of Science ®Google Scholar
• Hreczuk-Hirst D, Chicco D, German L, et al. Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. Int J Pharm. 2001;230:57–66.
   PubMed Web of Science ®Google Scholar
• Hardwicke J, Ferguson EL, Moseley R, et al. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. J Control Release. 2008;130:275–283.
   PubMed Web of Science ®Google Scholar
• Duncan R, Gilbert HRP, Carbajo RJ, et al. Polymer masked-unmasked protein therapy (PUMPT). 1. Bioresponsive dextrin-trypsin and -MSH conjugates designed for α-amylase activation. Biomacromolecules. 2008;9:1146–1154.
   PubMed Web of Science ®Google Scholar
• Duncan R, Dimitrijevic S, Evagorou EG. The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharma Sci. 1996;6:237–263.
   Google Scholar
• Davis FF. The origin of pegnology. Adv Drug Deliv Rev. 2002;54:457–458.
   PubMed Web of Science ®Google Scholar
• Beck B, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–337.
   PubMed Web of Science ®Google Scholar
• Vella M, Pace D. Glycoconjugate vaccines: an update. Expert Opin Biol Ther. 2015;15:529–546.
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MABS. 2011;3:161–172.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Alley SC, Bilic S, et al. Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper. Bioanalysis. 2013;5:997–1006.
   PubMed Web of Science ®Google Scholar
• Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680–690.
   PubMed Web of Science ®Google Scholar
• Hurwitz ME, Diab A, Bernatchez C, et al. Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. J Clin Oncol. 2017;35(Suppl 6S):454.
   Google Scholar
• Diab A, Tannir NM, Bernatchez C, et al. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. J Clin Oncol. 2017;35(suppl):e14040.
   Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22:2848–2854.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Bullock AJ, Seery TE, et al. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). J Clin Oncol. 2017;35(Suppl):4008.
   Web of Science ®Google Scholar
• Mito JK, Ferrer JM, Brigman BE, et al. Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer. 2002;118:5320–5330.
   Web of Science ®Google Scholar
• Whitley MJ, Cardona DM, Lazarides AL, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016;8:320ra4.
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol. 2011;22:1–10.
   PubMed Web of Science ®Google Scholar
• Burris HA, Barve MA, Hamilton EP, et al. A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2. J Clin Oncol. 2017;35:TPS2606.
   Web of Science ®Google Scholar
• Lyman GH, Allcott K, Garcia J, et al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer. 2017;25:2619–2629.
   PubMed Web of Science ®Google Scholar
• Mahler LJ, DiBlasi R, Perez A, et al. On-body injector: an administration device for Pegfilgrastim. Clin J Oncol Nurs. 2017;21:121–122.
   PubMed Web of Science ®Google Scholar
• Muñoz-Garach A, Molina-Vega M, Tinahones FJ. How can a good idea fail? Basal insulin Peglispro [LY2605541] for the treatment of type 2 diabetes. Diabetes Ther. 2017;8:9–22.
   PubMed Web of Science ®Google Scholar
• Jolivalt CG, Rodriguez M, Wahren J, et al. Efficacy of a long-acting C-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice. Diabetes Obes Metab. 2015;17:781–788.
   PubMed Web of Science ®Google Scholar
• Li G, Zhao M, Zhao L. Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment. Drug Deliv. 2016;23:2860–2868.
   PubMed Web of Science ®Google Scholar
• Wiedermann CJ, Eisendle K. Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency. J Pharm Policy Pract. 2017;21:12.
   Google Scholar
• Hartog CS, Natanson C, Sun J, et al. Concerns over use of hydroxyethyl starch solutions. BMJ. 2014;349:g5981.
   PubMed Web of Science ®Google Scholar
• Cohen J, Belova A, Selmaj K, et al. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015;72:1433–1441.
   PubMed Web of Science ®Google Scholar
• Milani B, Gaspani S. Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C. GaBI J. 2013;2:194–203.
   Google Scholar
• Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim. [Internet]. 2017. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-pegfilgrastim
   Google Scholar
• Hoggatt J, Tate TA, Pelus LM. Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. Int J Nanomed. 2015;10:2647–2652.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Nair KV, Glajch JL, et al. Two decades of glatiramer acetate: from initial discovery to the current development of generics. J Neurol Sci. 2017;376:255–259.
   PubMed Web of Science ®Google Scholar
• Arvedson T, O’Kelly J, Yang B-B. Design rationale and development approach for Pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs. 2015;29:185–198.
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Bird C, Dougall T, et al. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. J Immunol Methods. 2015;416:17–28.
   PubMed Web of Science ®Google Scholar
• Israelachvili J. The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA. 1997;94:8378–8379.
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu M-R, Wan H-T. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull. 2014;37:335–339.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res. 2013;30:1729–1734.
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319–1323.
   PubMed Web of Science ®Google Scholar
• Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal Chem. 2016;88:11804–11812.
   PubMed Web of Science ®Google Scholar
• Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol. 2016;137:1610–1613.
   PubMed Web of Science ®Google Scholar
• Maier KE, Levy M. From selection hits to clinical leads: progress in aptamer discovery. Mol Ther-Methods Clin Develop. 2016;5:16014.
   PubMed Web of Science ®Google Scholar
• Pratten MK, Duncan R, Lloyd JB. Adsorptive and passive pinocytic uptake. In: Ockleford CJ, Whyte A., editors. Coated vesicles. Cambridge: Cambridge University Press; 1980. p. 179–218.
   Google Scholar
• Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991;60:257–280.
   PubMed Web of Science ®Google Scholar
• Sultana N, Arayne S, Saify ZS. Polyvinylpyrolidone as plasma expander. JPMA. 1978;28:147–153.
   Google Scholar
• Mohr W, Endres-Klein R. Do polyvinylpyrrolidone (PVP) deposits still occur in internal organs at the turn of the millennium? Observations on three patients from the former USSR. Pathologe. 2002;23:386–388.
   PubMed Web of Science ®Google Scholar
• Chi CC, Wang SH, Kuo TT. Localized cutaneous polyvinylpyrrolidone storage disease mimicking cheilitis granulomatosa. J Cutan Pathol. 2006;33:454–457.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Schoetens F, et al. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105:460–475.
   PubMed Web of Science ®Google Scholar
• Conover C, Lejeune L, Linberg R, et al. Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Artif Cells Blood Substit Immobil Biotechnol. 1996;24:599–611.
   PubMed Web of Science ®Google Scholar
• Bendele A, Seely J, Richey C, et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci. 1998;42:152–157.
   PubMed Web of Science ®Google Scholar
• Ivens IA, Achanzar W, Baumann A, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;43:959–983.
   PubMed Web of Science ®Google Scholar
• EMA/CHMP/SWP/647258/2012. CHMP Safety Working Party’s response to the PDCO regarding the use of PEGylated drug products in the paediatric population. 2012.
   Google Scholar
• Ramos-Leví AM, Bernabeu I, Álvarez-Escolá C, et al. Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin Endocrinol (Oxf). 2016;84:540–550.
   PubMed Web of Science ®Google Scholar
• Richardson SCW, Pattrick NG, Lavignac N, et al. Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo. J Control Release. 2010;142:78–88.
   PubMed Web of Science ®Google Scholar
• Duncan R, Pratten MK, Cable HC, et al. Effect of molecular size of 125I-labelled poly(vinylpyrrolidone) on its pinocytosis by rat visceral yolk sacs and rat peritoneal macrophages. Biochem J. 1980;196:49–55.
   Web of Science ®Google Scholar
• Clarke RM, Hardy RN. The use of [125-I]polyvinyl pyrrolidone K. 60 in the quantitative assessment of the uptake of macromolecular substances by the intestine of the young rat. J Physiol. 1969;204:113–125.
   PubMed Web of Science ®Google Scholar
• Cheng T-L, Chuang K-H, Chen B-M, et al. Analytical measurement of PEGylated molecules. Bioconjug Chem. 2012;23:881–899.
   PubMed Web of Science ®Google Scholar
• Lin WW, Hsieh Y-C, Cheng Y-A, et al. Optimization of an anti-poly(ethylene glycol) (anti-PEG) cell-based capture system to quantify PEG and PEGylated molecules. Anal Chem. 2016;88:12371–12379.
   PubMed Web of Science ®Google Scholar
• Gong J, Gu X, Achanzar WE, et al. Quantitative analysis of polyethylene glycol (PEG) and PEGylated proteins in animal tissues by LC-MS/MS coupled with in-source CID. Anal Chem. 2014;86:7642–7649.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292.
   PubMed Web of Science ®Google Scholar
• Menjoge AR, Rinderknecht A, Navath RS, et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J Control Rel. 2011;150:326–338.
   PubMed Web of Science ®Google Scholar
• Hassfurther RL, TerHune TN, Canning PC. Efficacy of polyethylene glycol-conjugated bovine granulocyte colony-stimulating factor for reducing the incidence of naturally occurring clinical mastitis in periparturient dairy cows and heifers. Am J Vet Res. 2015;76:231–238.
   PubMed Web of Science ®Google Scholar
• Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8:2101–2141.
   PubMed Web of Science ®Google Scholar
• Rivera Gil P, Hühn D, del Mercato LL, et al. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010;62:115–125.
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65:80–88.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:1–12.
   Web of Science ®Google Scholar
• Phillips E, Penate-Medina O, Zanzonico PB, et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014;6:260ra149.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. [Internet]; 2014. [cited 28 Jul 2017]. Available from: https://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm
   Google Scholar
• Ehmann F, Sakai-Kato K, Duncan R, et al. Next generation nanomedicines and nano-similars: EU Regulators’ initiatives relating to the development and evaluation of nanomedicines. Nanomedicine. 2013;8:849–856.
   PubMed Web of Science ®Google Scholar
• Ehmann F, Pita R. The EU is ready for non-biological complex medicinal products. GaBI J. 2016;5:30–35.
   Google Scholar
• Tyner KM, Zheng N, Choi S, et al. How has CDER prepared for the nano revolution? A review of risk assessment, Regulatory research, and guidance activities. AAPS J. 2017;19:1071–1083.
   PubMed Web of Science ®Google Scholar
• D'Mello SR, Cruz CN, Chen ML, et al. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12:523–529.
   PubMed Web of Science ®Google Scholar
• Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Del Rev. 2009;61:1220–1231.
   PubMed Web of Science ®Google Scholar
• Kapoor M, Lee SL, Tyner KM. Liposomal drug product development and quality: current US experience and perspective. AAPS J. 2017;19:632–641.
   PubMed Web of Science ®Google Scholar
• EMA. EMA Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. [Internet]; 2013. [cited 28 Jul 2017]. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500140351.pdf.
   Google Scholar
• Chen ML, John M, Lee SL, et al. Development considerations for nanocrystal drug products. AAPS J. 2017;19:642–651.
   PubMed Web of Science ®Google Scholar
• EMA Joint MHLW. Joint MHLW. EMA reflection paper on the development of block copolymer micelle medicinal products. [Internet]; 2013. [cited 28 Jul 2017]. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/02/WC500138390.pdf.
   Google Scholar
• Tyner KM, Zou P, Yang X, et al. Product quality for nanomaterials: current U.S. experience and perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:640–654.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Stegemann S, Weinstein V, et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 2014;16:15–21.
   PubMed Web of Science ®Google Scholar
• Hussaarts L, Mühlebach S, Shah VP, et al. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Ann NY Acad Sci. Forthcoming. [cited 2017 Apr 26]. doi: 10.1111/nyas.13347.
   Web of Science ®Google Scholar
• Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113:823–839.
   PubMed Web of Science ®Google Scholar
• Kamel Boulos MN, Le Blond J. On the road to personalised and precision geomedicine: medical geology and a renewed call for interdisciplinarity. Int J Health Geogr. 2016;15:5.
   PubMed Web of Science ®Google Scholar
• Duncan R. Nanomedicine(s) and their regulation: an overview. In: Fadeel B, editor. Handbook of safety assessment of nanomaterials – from toxicological testing to personalized medicine. Singapore: Pan Stanford Publishing Pte. Ltd; 2015. p. 1–41.
   Google Scholar
• Crist RM, Grossman JH, Patri AK, et al. Common pitfalls in nanotechnology: lessons learned from NCI's nanotechnology characterization laboratory. Integr Biol (Camb). 2013;5:66–73.
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Torchilin V, Patri AK, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res. 2014;18:3229–3241.
   Web of Science ®Google Scholar
• Schell RF, Sidone BJ, Caron WP, et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine. 2014;10:109–117.
   PubMed Web of Science ®Google Scholar
• Harrison RK. The high drug attrition rate, 90–95% of drugs entering clinical development fail, is regularly discussed (Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15:817–818.
   PubMed Web of Science ®Google Scholar
• Mullard A. 2016 EMA drug approval recommendations. Nat Rev Drug Discov. 2017;16:77.
   Web of Science ®Google Scholar
• Mullard A. 2016 FDA drug approvals. Nat Rev Drug Discov. 2017;16:73–76.
   PubMed Web of Science ®Google Scholar
• Scannell JW, Bosley J. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One. 2016;11:e0147215.
   PubMed Web of Science ®Google Scholar
• Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35:222–229.
   PubMed Web of Science ®Google Scholar
• Bass AS. A historical view and vision into the future of the field of safety pharmacology. Handb Exp Pharmacol. 2015;229:3–45.
   PubMedGoogle Scholar
• Collins AR, Annangi B, Rubio L, et al. High throughput toxicity screening and intracellular detection of nanomaterials. Wires Nanomed Nanobiotechnol. 2017;9:e1413.
   Web of Science ®Google Scholar
• Drews J. Drug discovery: a historical perspective. Science. 2000;287:1960–1964.
   PubMed Web of Science ®Google Scholar
• Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–968.
   PubMed Web of Science ®Google Scholar
• Torre BG, Albericio F. The pharmaceutical industry in 2016. An analysis of FDA drug approvals from a perspective of the molecule type. Molecules. 2017;22:368.
   Web of Science ®Google Scholar
• Mahmood I. Pharmacokinetic considerations in designing pediatric studies of proteins, antibodies, and plasma-derived products. Am J Therap. 2016;23:e1043–e1056.
   PubMed Web of Science ®Google Scholar
• Freedman LP, Gibson MC. The impact of preclinical irreproducibility on drug development. Clin Pharmacol Ther. 2015;97:16–18.
   PubMed Web of Science ®Google Scholar
• Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531–533.
   PubMed Web of Science ®Google Scholar
• Horvath P, Aulner N, Bickle M, et al. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016;15:751–769.
   PubMed Web of Science ®Google Scholar
• Loadman PM, Bibby MC, Double JA, et al. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin Cancer Res. 1999;5:3682–3688.
   PubMed Web of Science ®Google Scholar
• Duncan R, Sat-Klopsch Y-N, Burger AM, et al. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol. 2013;72:417–427.
   PubMed Web of Science ®Google Scholar
• PricewaterhouseCoopers. Pharma 2020: The vision Which path will you take? [Internet]; 2007. [cited 28 Jul 2017]. Available from: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/pharma-2020/pharma-2020-vision-path.html.
   Google Scholar
• Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16:771–783.
   PubMed Web of Science ®Google Scholar
• Crosby P. Quality is free: the art of making quality certain. New York: McGraw Hill; 1979.
   Google Scholar
• Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26–34.
   PubMed Web of Science ®Google Scholar
• Zuckerman JE, Gritli I, Tolcher A, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA. 2014;111:11449–11454.
   PubMed Web of Science ®Google Scholar
• Duncan R, Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin Pharmacokinet. 1994;27:290–306.
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701.
   PubMed Web of Science ®Google Scholar
• Duncan R, Cable HC, Lloyd JB, et al. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci Rep. 1983;2:1041–1046.
   Web of Science ®Google Scholar
• Shaffer SA, Baker-Lee C, Kennedy J, et al. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol. 2007;59:537–548.
   PubMed Web of Science ®Google Scholar
• Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:623–630.
   PubMed Web of Science ®Google Scholar
• Perez EA, Awada A, O'Shaughnessy J, et al. Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. J Clin Oncol. 2015;33:1001.
   Web of Science ®Google Scholar
• Seymour LW, Ulbrich K, Styger PS, et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer. 1994;70:636–641.
   PubMed Web of Science ®Google Scholar
• Sarapa N, Britto MR, Speed W, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol. 2003;52:424–430.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243–254.
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Gabizon AA. Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Front Immunol. 2017;68:416.
   Google Scholar
• Lee H, Shields AF, Siegel BA, et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res. 2017. Forthcoming. [cited 2017 Jun 7]. doi: 10.1158/1078-0432.CCR-16-3193.
   Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508–1516.
   PubMed Web of Science ®Google Scholar
• Khan N, Hills RK, Virgo P. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 2017;31:1059–1068.
   PubMed Web of Science ®Google Scholar
• Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs. 2014;6:859–870.
   PubMed Web of Science ®Google Scholar
• Diamantis N, Banerji U. Antibody-drug conjugates-an emerging class of cancer treatment. Br J Cancer. 2016;114:362–367.
   PubMed Web of Science ®Google Scholar
• Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209.
   PubMed Web of Science ®Google Scholar
• Duncan R, Lloyd JB. Pinocytosis in the rat visceral yolk sac. Effects of temperature, metabolic inhibitors and some other modifiers. Biochim Biophys Acta. 1978;544:647–655.
   PubMed Web of Science ®Google Scholar
• Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008;8:835–850.
   PubMed Web of Science ®Google Scholar
• Lanzetti L, Di Fiore PP. Behind the scenes: endo/exocytosis in the acquisition of metastatic traits. Cancer Res. 2017;77:1813–1817.
   PubMed Web of Science ®Google Scholar
• Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518–6548.
   PubMed Web of Science ®Google Scholar
• Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res. 1979;14:81–87.
   PubMedGoogle Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Rel. 2001;74:47–61.
   PubMed Web of Science ®Google Scholar
• Breslow DS, Edwards EI, Newburg NR. Divinyl ether-maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity. Nature. 1973;246:160–162.
   PubMed Web of Science ®Google Scholar
• Regelson W. Future direction of synthetic polyanions (pyran copolymer). Cancer Treat Rep. 1978;62:1853–1856.
   PubMedGoogle Scholar
• Ferguson EL, Duncan R. Dextrin-phospholipase A2: a novel bioresponsive anticancer conjugate. Biomacromolecules. 2009;10:1358–1364.
   PubMed Web of Science ®Google Scholar